Alfasigma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
54 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jyseleca (filgotinib) / Gilead
2020-002802-21: Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient’s as well as an economic point of view. Tailoring of treatment is done by taking the presence of autoantibodies and the quick response to glucocorticoids and JAK inhibitors into account. Het vergelijken van de effectiviteit van behandeling op maat met de huidige standaard zorg, vanuit een klinisch oogpunt, patiënten- en economisch perspectief. bij nieuw gediagnosticeerde reumatoïde artritis patiënten. Individualisering van de behandeling wordt gedaan door rekening te houden met de aan- of afwezigheid van autoantistoffen en het vroege effect van glucocorticoïden en JAK inhibitoren op de ziekte-activiteit.

Ongoing
4
300
Europe
Filgotinib, Tablet, Jyseleca
Erasmus Medical Center, Galapagos N.V.
Rheumatoid arthritis according to 2010 criteria Reumatoïde artritis volgens de 2010 classificatie criteria, Symmetrical (small) joint inflammation with or without auto-antibodies (i.e. rheumatoid factor and/or anti-citrullinated protein antibodies) Gewrichtsontstekings aan meerdere (kleine) gewrichten met of zonder auto-antistoffen (reumafactor en/of anti-CCP), Diseases [C] - Immune System Diseases [C20]
 
 
2021-006007-15: Januse kinase Inhibition with Filgotinib to Silence Autoreactive B cells in Rheumatoid Arthritis Het remmen van Janus kinases door filgotinib om B cellen gericht tegen gecitrullineerde eiwitten bij reumatoïde artritis tot rust te brengen

Not yet recruiting
4
46
Europe
Jyseleca, Tablet, Jyseleca
Leiden University Medical Center (LUMC), Galapagos NV
patients with ACPA-positieve active RA, patients with ACPA-positieve active RA, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
BACH, NCT04985435: Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA

Recruiting
4
100
Europe
Filgotinib, Jyseleca, Anti-Tumor Necrosis Factor Alpha Drug (Product), Adalimumab (Humira) Etanercept (Enbrel), 50 patients will have a Free Choice between Filgotinib and anti TNF
R.Bos, Galapagos NV, Medical Centre Leeuwarden, Leiden University Medical Center
Rheumatoid Arthritis
03/23
04/23
FILRA, NCT06527534: Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Recruiting
4
30
Europe
Filgotinib, Adalimumab
Universita di Verona
Rheumatoid Arthritis
07/25
09/25
NCT06625242: A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis

Recruiting
4
150
RoW
Filgotinib Maleate, Jyseleca
Eisai Korea Inc.
Rheumatoid Arthritis
06/25
10/25
JAK-TAP, NCT06687551: JAK Inhibitor Dose TAPering Strategy Study

Not yet recruiting
4
308
NA
Baricitinib (LY3009104) 4 mg, filgotinib 200mg/day, Tofacitinib 5 mg twice daily, Upadacitinib 15 MG
University Hospital, Toulouse
Rhumatoid Arthisis
04/29
04/29
JAKAR, NCT05502731 / 2021-006007-15: Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis

Not yet recruiting
4
40
Europe
Filgotinib, Jyseleca, Adalimumab, Hyrimoz
Leiden University Medical Center, Galapagos NV
Rheumatoid Arthritis
03/25
10/25
NCT06964113: A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Recruiting
4
94
RoW
Filgotinib Maleate, Jyseleca
Eisai Korea Inc., Gilead Sciences
Ulcerative Colitis
11/27
11/27
TRANSFORM, NCT05090410: Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Recruiting
3
400
Japan
filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly
Atsushi Kawakami, Gilead Sciences
Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor, Musculoskeletal Ultrasound, Biomarker
02/23
12/23
DIVERSITYLTE, NCT02914600 / 2016-002763-34: Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Terminated
3
1188
Europe, Canada, Japan, US, RoW
Filgotinib, GS-6034, GLPG0634, Jyseleca®, Placebo
Galapagos NV, Gilead Sciences
Crohn's Disease
08/23
08/23
CAPYBARA, NCT05479058 / 2022-000719-30: A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

Terminated
3
22
Europe, US, RoW
Filgotinib, GS-6034, GLPG0634, Placebo
Galapagos NV, Galapagos NV
Ulcerative Colitis
10/23
10/23
2022-000719-30: A study evaluating the effect of filgotinib dose de-escalation in patientswith ulcerative colitis in remission Badanie dotyczące obniżenia dawki filgotynibu u pacjentów z wrzodziejącym zapaleniem jelita grubego w remisji

Not yet recruiting
3
80
Europe, RoW
Filgotinib, GLPG0634, Film-coated tablet, Jyseleca
Galapagos NV, GALAPAGOS NV, Galapagos NV
ulcerative colitis (UC), ulcerative colitis, Diseases [C] - Digestive System Diseases [C06]
 
 
Olinguito, NCT05785611: A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

Active, not recruiting
3
495
Europe, RoW
Filgotinib, GS-6034, GLPG0634, Placebo
Alfasigma S.p.A.
Axial Spondyloarthritis
09/24
07/26
FINCH 4, NCT03025308 / 2016-003630-25: Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Hourglass Mar 2021 - Dec 2021 : Long term safety data from FINCH 4 trial for rheumatoid arthritis
Completed
3
2731
Europe, Canada, Japan, US, RoW
Filgotinib, GS-6034, GLPG0634, Placebo to match filgotinib
Alfasigma S.p.A., Gilead Sciences
Rheumatoid Arthritis
05/25
05/25
Galapeduca, NCT06865417: A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

Not yet recruiting
3
80
Europe, RoW
Filgotinib
Alfasigma S.p.A.
Ulcerative Colitis
06/27
06/28
SELECTIONLTE, NCT02914535 / 2016-002765-58: Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Active, not recruiting
3
1173
Europe, Canada, Japan, US, RoW
Filgotinib, GS-6034, GLPG0634, Placebo
Alfasigma S.p.A., Gilead Sciences
Ulcerative Colitis
09/26
09/26
2017-001485-17: A Phase 2 trial assessing the effectiveness (efficacy) and safety of Filgotinib compared to placebo in subjects with active non-infectious Uveitis

Not yet recruiting
2
248
Europe
Filgotinib, GS-6034, Film-coated tablet
Gilead Sciences, Inc., Gilead Sciences, Inc.
Non-infectious Uveitis, Non-infectious Uveitis, Diseases [C] - Eye Diseases [C11]
 
 
MANTA, NCT03201445 / 2017-000402-38: Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

Checkmark From MANTA trial in moderately to severely active ulcerative colitis
Mar 2021 - Mar 2021: From MANTA trial in moderately to severely active ulcerative colitis
Checkmark For MANTA trial in males with inflammatory bowel disease
Aug 2020 - Aug 2020: For MANTA trial in males with inflammatory bowel disease
Terminated
2
139
Europe, US, RoW
Filgotinib, Placebo, Standard of Care
Galapagos NV, Gilead Sciences
Inflammatory Bowel Disease
11/20
10/23
MANTA-RAy, NCT03926195 / 2018-003933-14: Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis

Checkmark From MANTA-RAy trial for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis
Mar 2021 - Mar 2021: From MANTA-RAy trial for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis
Checkmark For MANTA-Ray trial in males with rheumatoid Arthritis, psoriatic Arthritis, ankylosing Spondylitis, or non-radiographic Axial Spondyloarthritis
Aug 2020 - Aug 2020: For MANTA-Ray trial in males with rheumatoid Arthritis, psoriatic Arthritis, ankylosing Spondylitis, or non-radiographic Axial Spondyloarthritis
Completed
2
109
Europe, RoW
Filgotinib, GS-6034, Jyseleca®, Placebo, Standard of Care
Galapagos NV, Gilead Sciences
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographical Axial Spondyloarthritis
08/20
05/23
DARWIN3, NCT02065700 / 2012-003655-11: Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

Checkmark DARWIN3 trial for RA at ACR 2017
Nov 2017 - Nov 2017: DARWIN3 trial for RA at ACR 2017
Checkmark Interim data from DARWIN 3 trial for RA at EULAR 2017
Jun 2017 - Jun 2017: Interim data from DARWIN 3 trial for RA at EULAR 2017
Completed
2
739
Europe, US, RoW
Filgotinib, GS-6034, GLPG0634
Galapagos NV, Gilead Sciences
Rheumatoid Arthritis
01/23
01/23
DRIMID, NCT06285539: Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Recruiting
2
60
Europe
Filgotinib
UMC Utrecht, Alfasigma S.p.A., ReumaNederland, Autoimmune Research and Collaboration Hub
Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease
12/26
12/26
NCT06043739: Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Completed
1
12
Canada
Filgotinib, GS-6034, GLPG0634, Jyseleca
Galapagos NV
Bioavailability
10/23
11/23
NCT06222034: Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Recruiting
1
10
Europe
Filgotinib, GS-6034, GLPG0634, Jyseleca
Alfasigma S.p.A.
Juvenile Idiopathic Arthritis
01/26
08/26
FIL-M082-501, NCT06246123: A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

Recruiting
N/A
2040
RoW
Non-interventional
Eisai Korea Inc.
Arthritis, Rheumatoid, Colitis, Ulcerative
07/27
07/27
NCT05119452: Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis

Not yet recruiting
N/A
85
NA
Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD), b/tsDMARD: Adalimumab, Infliximab, Golimumab, Certolizumab pegol, Tocilizumab, Sarilumab, Etanercept, Anakinra, Filgotinib, Updacitinib, Tofacitinib, Baricitinib
Medical University of Vienna, Medical University of Graz, Medical University Innsbruck, Hospital Hietzing, Krankenhaus Bruneck
Rheumatoid Arthritis
09/24
09/24
FILOSOPHY, NCT04871919: Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

Active, not recruiting
N/A
1304
Europe
Filgotinib, Jyseleca
Alfasigma S.p.A.
Rheumatoid Arthritis
06/28
06/28
TEMPO, NCT05697159: 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

Recruiting
N/A
20
Europe
NHS Greater Glasgow and Clyde, Galapagos NV
Rheumatoid Arthritis, Sickness Behavior, Inflammatory Disease, Autoimmune, Pain, Chronic
07/25
10/25
PARROTFISH, NCT05323591: Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

Active, not recruiting
N/A
155
Europe
Filgotinib, Jyseleca
Alfasigma S.p.A.
Rheumatoid Arthritis
09/25
09/25
GALOCEAN, NCT05817942: Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

Recruiting
N/A
600
Europe
Filgotinib
Alfasigma S.p.A.
Ulcerative Colitis
12/27
12/27
STEER, NCT05653791: Early Intestinal Ultrasound in Predicting Treatment Response to Filgotinib in Ulcerative Colitis

Active, not recruiting
N/A
20
Europe
Intestinal ultrasound
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Galapagos NV
Ulcerative Colitis
04/24
10/24
Xifaxan EIR (rifaximin extended intestinal release) / Bausch Health, Alfasigma
2017-003722-33: Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in Patients with Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test Studio clinico di fase II, condotto in siti differenti, con assegnazione random del trattamento, in cui né il paziente né il medico conoscono il trattamento assegnato, attivo o placebo, per valutare efficacia e sicurezza di Rifaximina compresse da 400 mg a rilascio ritardato in pazienti con rosacea papulo-pustolosa moderata-severa e positività al breath test al lattulosio.

Not yet recruiting
2
228
Europe
Rifaximin delayed release 400 mg, Rifaximin-EIR, Coated tablet
ALFASIGMA S.P.A., ALFASIGMA S.P.A.
Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test Rosacea papulo-pustolosa moderata-severa e positività al breath test al lattulosio, Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test Rosacea papulo-pustolosa moderata-severa e positività al breath test al lattulosio, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05150587: Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

Completed
2
216
US
Rifaximin, Placebo
Alfasigma S.p.A., bioRASI, LLC
Papulopustular Rosacea
10/22
10/22
Sulonex (sulodexide) / Alfasigma
ChiCTR-TRC-09000559: A randomized double-blind parallel placebo trial to evaluate the efficacy and safety of sulodexide on diabetes with marcoalbuminuria.

Completed
4
160
 
Placebo 2 capsules bid for 48 weeks ;Sulodexide 2 capsules bid (100mg/day) for 48 weeks
West China Hospital, Sichuan University; Alfa Wassermann Inc. Italy, Alfa Wassermann Inc. Italy
Diabetes with marcoalbuminuria
 
 
2006-004043-35: Effects of Sulodexide on damaged endothelial Glycocalyx in pAtients with Diabetes Mellitus type II; Reversing damage.

Ongoing
4
26
Europe
Sulodexide, Sulodexide, Sulodexide
diabetes mellitus type II with and without microalbuminuria, damaged glycocalyx
 
 
2015-005113-73: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes

Ongoing
4
52
Europe
Tablet, Capsule, Micardis, Jardiance, Trajenta, Vessel Due F
University Medical Center Groningen, UMCG
Type 2 diabetes with albuminuria, Type 2 diabetes with albumin in urine., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2015-005691-26: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes

Ongoing
4
26
Europe
Micardis, Jardiance, Trajenta, Vessel Due F
University Medical Center Groningen, University Medical Center Groningen
Type 1 diabetes with albuminuria, Type 1 diabetes with albumin in the urine, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
ChiCTR-IPC-15007029: A study of sulodexide in the treatment of elder patients with diabetic nephropathy (dn)

Not yet recruiting
4
60
 
slodexide 50mg bid po ;conventional treatment
zhejiang hospital; Zhejiang Hospital, self-preparation/drug supplied by pharmaceutical firms for free
diabetic nephropathy
 
 
NCT05252923: Endothelial Protection in Convalescent COVID-19 Patients

Terminated
4
2
RoW
Sulodexide
Pirogov Russian National Research Medical University
Endothelial Dysfunction, Inflammation, Thrombosis, COVID-19
09/22
12/22
2020-000110-15: Study on Sulodexide compared with placebo for the management of leg symptoms in patients with chronic venous disease

Not yet recruiting
3/4
624
RoW, Europe
Sulodexide 250 LSU, [Sulodexide], Capsule, soft, Vessel
Alfasigma S.p.A., ALFASIGMA S.P.A., Alfasigma S.p.A., ALFASIGMA S.P.A.
Chronic Venous Disease, Chronic Venous Disease, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2016-000783-42: A phase 3, prospective, open, pilot, monocentric study to evaluate the effect of sulodexide administered at registered dose on morphology and functional properties of the venous endothelium in patients with chronic venous insufficiency.

Ongoing
3
15
Europe
Capsule, soft, VESSEL DUE F, Sulodexide
Alfa Wassermann Polska Sp. z o.o., Alfa-Wassermann Polska Sp. z o.o.
chronic venous insufficiency, chronic venous insufficiency, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2019-000570-33: Sulodexide (VESSEL®) for the prevention of a recurrent episode of deep vein thrombosis and/or pulmonary embolism in elderly patients Utilizzo del Sulodexide (VESSEL®) per la prevenzione di un nuovo episodio in pazienti anziani che hanno avuto un primo episodio di trombosi venosa profonda e/o embolia polmonare

Not yet recruiting
3
1455
Europe
Vessel, [Sulodexide], Capsule, soft, VESSEL - 250 ULS CAPSULE MOLLI 50 CAPSULE
FONDAZIONE ARIANNA ANTICOAGULAZIONE, ALFASIGMA
Prevention of recurrence after a first episode of VTE Prevenzione della recidiva dopo un primo episodio di tromboembolismo venoso, Prevention of recurrent episode of deep vein thrombosis with or without pulmonary embolism in elderly patients Prevenzione di un nuovo episodio di trombosi venosa profonda con o senza embolia polmonare in pazienti anziani, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT05371925: Endothelial Protection in Post COVID-19 Patients With Sulodexide

Completed
3
206
RoW
Sulodexide, Vessel due F (Alfasgima SpA, Italy)
Centro Medico del Noroeste, Alfasigma S.p.A.
Post COVID-19, Endothelial Dysfunction, Thrombosis
02/24
04/24
2021-002311-64: Treatment of patients with chronic venous disease of the lower extremities using sulodexide Terapie pacientů s chronickým žilním onemocněním dolních končetin pomocí sulodexidu

Not yet recruiting
3
290
RoW
Vessel, Capsule, soft, Vessel
ALFASIGMA CZECH s.r.o., ALFASIGMA CZECH s.r.o.
Chronic primary venous disease of the lower limbs chronické primární žilní onemocnění dolních končetin, Long-term venous disease of the lower limbs Dlouhodobé žilní onemocnění dolních končetin, Diseases [C] - Cardiovascular Diseases [C14]
 
 
Jason, NCT04257487: Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Study)

Recruiting
3
1455
Europe
Sulodexide, VESSEL®, Sulodexide and placebo, VESSEL® and placebo, Placebo, 2 soft capsule of placebo BDI for 12 months
Arianna Anticoagulazione Foundation
Venous Thromboembolism, Anticoagulant, Elderly
12/25
01/27
SuloPrima, NCT05005052: Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities

Recruiting
3
290
RoW
Vessel, Placebo
Value Outcomes Ltd., Alfasigma S.p.A.
Chronic Venous Disease, Chronic Insufficiency Venous
12/23
12/23
NCT06982196: Sulodexide in Controlling the Recurrence of Psoriasis

Enrolling by invitation
3
160
RoW
Sulodexide, Vessel Due F (international brand), Placebo, Matching placebo for sulodexide soft capsules
Xijing Hospital
Psoriasis (PsO), Randomised Controlled Trial
06/26
12/27
2020-002864-30: Sulodexide for chronic heart failure

Not yet recruiting
2
64
Europe
Capsule, VESSEL DUE F
Amsterdam UMC, location AMC, Dutch Heart Foundation
Chronic heart failure, Chronic heart failure, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2022-001958-36: A prospective, randomised, placebo-controlled, investigator-initiated study of the effect of Sulodexide on endothelial protection in convalescent COVID-19 patients. Prospektív, randomizált, placebo kontrollált, vizsgálók által kezdeményezett vizsgálat a Sulodexide endotheliális védelemre gyakorolt hatására gyógyuló COVID-19 betegeknél.

Ongoing
2
200
Europe
Vessel due F, Capsule, soft, Vessel due F
Corporativo de Servicios Médicos Especializados S.A de C.V V (Centro Médico del Noroeste), Pécsi Tudományegyetem; Szegedi Tudományegyetem
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus 2 (SARS-CoV-2) and, thus, being a novel cause of sepsis and the the poor outcome of patients with sepsis was related to systemic microvascular endothelial dysfunction in the vital organs of the body. A koronavírus (SARS-CoV-2) által okozott fertőző betegség kedvezőtlen kimenetelét a létfontosságú szervek szisztémás mikrovaszkuláris endotél diszfunkciójával hozzák kapcsolatba., Systemic microvascular endothelial dysfunction of poor outcome of COVID-19 patients with sepsis COVID-19 fertőzésben szenvedő betegek rossz kimenetelű szisztémás mikrovaszkuláris endotél diszfunkciója, Diseases [C] - Cardiovascular Diseases [C14]
 
 
ChiCTR2200057699: A prospective, controlled, post-marketing exploratory clinical study to evaluate the safety and efficacy of sulodexide in the treatment of adult patients with simple hemodialysis access stenosis after percutaneous transluminal angioplasty

Not yet recruiting
N/A
90
 
Sulodexide soft capsule, oral preparation, 250LSU each time, 2 times a day (morning and evening), continuous medication for a total of 24 weeks. ;Sulodexide soft capsule, oral preparation, 500LSU each time, 2 times a day (morning and evening), continuous medication for a total of 24 weeks. ;None
The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, China Association of Gerontology and Geriatrics
simple hemodialysis access stenosis in adults
 
 
NCT05654233: The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

Not yet recruiting
N/A
120
RoW
Sulodexide
Chengdu University of Traditional Chinese Medicine
Vascular Diseases, Peripheral, Venous Insufficiency of Leg, Varicose Veins of Lower Limb
08/23
09/23
ChiCTR2300067473: Application of Sulodexide in the Treatment of Refractory Posner-Schlossman Syndrome:A self-controlled Study

Not yet recruiting
N/A
16
 
sulodexide
The Eye of Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University; The Eye of Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, self-finance
Posner-Schlossman Syndrome
 
 
ChiCTR2200060833: Clinical observation on the treatment of proteinuria after renal transplantation with Sulodexide soft capsule

Recruiting
N/A
120
 
Oral sulodexide softgel
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology; Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, ALFA WASSERMANN Pharmaceuticals, Italy
proteinuria after renal transplantation
 
 
ChiCTR2400079929: Changes of vascular endothelial glycocalyx in sepsis and the protective effect of glycosaminoglycan

Not yet recruiting
N/A
70
 
Both groups followed the clinical guidelines, improved pathogenic microorganism monitoring, clearance of infection, early use of antibiotics and hemodynamic support. On this basis, the observation group was treated with glycosaminoglycan (Sulodexide, Alphagemar)[2ml:600LSU/time,1 time /d].; All patients followed the clinical guidelines, improved pathogenic microorganism monitoring, clearance of infection foci, early use of antibiotics and hemodynamic support.
Affiliated Hospital of Hangzhou Normal University; Affiliated Hospital of Hangzhou Normal University, Hangzhou city technology bureau to guide project (20220919 y023)
sepsis
 
 
ACTRN12611000721909: Sulodexide effect on walking ability in patients with intermittent claudication

Not yet recruiting
N/A
50
 
Georges Tabet, Georges Tabet
Intermittent claudication, Peripheral arterial occlusive disease
 
 
brilacidin rectal / Innovation Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jyseleca (filgotinib) / Gilead
2020-002802-21: Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient’s as well as an economic point of view. Tailoring of treatment is done by taking the presence of autoantibodies and the quick response to glucocorticoids and JAK inhibitors into account. Het vergelijken van de effectiviteit van behandeling op maat met de huidige standaard zorg, vanuit een klinisch oogpunt, patiënten- en economisch perspectief. bij nieuw gediagnosticeerde reumatoïde artritis patiënten. Individualisering van de behandeling wordt gedaan door rekening te houden met de aan- of afwezigheid van autoantistoffen en het vroege effect van glucocorticoïden en JAK inhibitoren op de ziekte-activiteit.

Ongoing
4
300
Europe
Filgotinib, Tablet, Jyseleca
Erasmus Medical Center, Galapagos N.V.
Rheumatoid arthritis according to 2010 criteria Reumatoïde artritis volgens de 2010 classificatie criteria, Symmetrical (small) joint inflammation with or without auto-antibodies (i.e. rheumatoid factor and/or anti-citrullinated protein antibodies) Gewrichtsontstekings aan meerdere (kleine) gewrichten met of zonder auto-antistoffen (reumafactor en/of anti-CCP), Diseases [C] - Immune System Diseases [C20]
 
 
2021-006007-15: Januse kinase Inhibition with Filgotinib to Silence Autoreactive B cells in Rheumatoid Arthritis Het remmen van Janus kinases door filgotinib om B cellen gericht tegen gecitrullineerde eiwitten bij reumatoïde artritis tot rust te brengen

Not yet recruiting
4
46
Europe
Jyseleca, Tablet, Jyseleca
Leiden University Medical Center (LUMC), Galapagos NV
patients with ACPA-positieve active RA, patients with ACPA-positieve active RA, Diseases [C] - Musculoskeletal Diseases [C05]
 
 
BACH, NCT04985435: Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA

Recruiting
4
100
Europe
Filgotinib, Jyseleca, Anti-Tumor Necrosis Factor Alpha Drug (Product), Adalimumab (Humira) Etanercept (Enbrel), 50 patients will have a Free Choice between Filgotinib and anti TNF
R.Bos, Galapagos NV, Medical Centre Leeuwarden, Leiden University Medical Center
Rheumatoid Arthritis
03/23
04/23
FILRA, NCT06527534: Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

Recruiting
4
30
Europe
Filgotinib, Adalimumab
Universita di Verona
Rheumatoid Arthritis
07/25
09/25
NCT06625242: A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis

Recruiting
4
150
RoW
Filgotinib Maleate, Jyseleca
Eisai Korea Inc.
Rheumatoid Arthritis
06/25
10/25
JAK-TAP, NCT06687551: JAK Inhibitor Dose TAPering Strategy Study

Not yet recruiting
4
308
NA
Baricitinib (LY3009104) 4 mg, filgotinib 200mg/day, Tofacitinib 5 mg twice daily, Upadacitinib 15 MG
University Hospital, Toulouse
Rhumatoid Arthisis
04/29
04/29
JAKAR, NCT05502731 / 2021-006007-15: Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis

Not yet recruiting
4
40
Europe
Filgotinib, Jyseleca, Adalimumab, Hyrimoz
Leiden University Medical Center, Galapagos NV
Rheumatoid Arthritis
03/25
10/25
NCT06964113: A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Recruiting
4
94
RoW
Filgotinib Maleate, Jyseleca
Eisai Korea Inc., Gilead Sciences
Ulcerative Colitis
11/27
11/27
TRANSFORM, NCT05090410: Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Recruiting
3
400
Japan
filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly
Atsushi Kawakami, Gilead Sciences
Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor, Musculoskeletal Ultrasound, Biomarker
02/23
12/23
DIVERSITYLTE, NCT02914600 / 2016-002763-34: Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

Terminated
3
1188
Europe, Canada, Japan, US, RoW
Filgotinib, GS-6034, GLPG0634, Jyseleca®, Placebo
Galapagos NV, Gilead Sciences
Crohn's Disease
08/23
08/23
CAPYBARA, NCT05479058 / 2022-000719-30: A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

Terminated
3
22
Europe, US, RoW
Filgotinib, GS-6034, GLPG0634, Placebo
Galapagos NV, Galapagos NV
Ulcerative Colitis
10/23
10/23
2022-000719-30: A study evaluating the effect of filgotinib dose de-escalation in patientswith ulcerative colitis in remission Badanie dotyczące obniżenia dawki filgotynibu u pacjentów z wrzodziejącym zapaleniem jelita grubego w remisji

Not yet recruiting
3
80
Europe, RoW
Filgotinib, GLPG0634, Film-coated tablet, Jyseleca
Galapagos NV, GALAPAGOS NV, Galapagos NV
ulcerative colitis (UC), ulcerative colitis, Diseases [C] - Digestive System Diseases [C06]
 
 
Olinguito, NCT05785611: A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

Active, not recruiting
3
495
Europe, RoW
Filgotinib, GS-6034, GLPG0634, Placebo
Alfasigma S.p.A.
Axial Spondyloarthritis
09/24
07/26
FINCH 4, NCT03025308 / 2016-003630-25: Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Hourglass Mar 2021 - Dec 2021 : Long term safety data from FINCH 4 trial for rheumatoid arthritis
Completed
3
2731
Europe, Canada, Japan, US, RoW
Filgotinib, GS-6034, GLPG0634, Placebo to match filgotinib
Alfasigma S.p.A., Gilead Sciences
Rheumatoid Arthritis
05/25
05/25
Galapeduca, NCT06865417: A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

Not yet recruiting
3
80
Europe, RoW
Filgotinib
Alfasigma S.p.A.
Ulcerative Colitis
06/27
06/28
SELECTIONLTE, NCT02914535 / 2016-002765-58: Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Active, not recruiting
3
1173
Europe, Canada, Japan, US, RoW
Filgotinib, GS-6034, GLPG0634, Placebo
Alfasigma S.p.A., Gilead Sciences
Ulcerative Colitis
09/26
09/26
2017-001485-17: A Phase 2 trial assessing the effectiveness (efficacy) and safety of Filgotinib compared to placebo in subjects with active non-infectious Uveitis

Not yet recruiting
2
248
Europe
Filgotinib, GS-6034, Film-coated tablet
Gilead Sciences, Inc., Gilead Sciences, Inc.
Non-infectious Uveitis, Non-infectious Uveitis, Diseases [C] - Eye Diseases [C11]
 
 
MANTA, NCT03201445 / 2017-000402-38: Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

Checkmark From MANTA trial in moderately to severely active ulcerative colitis
Mar 2021 - Mar 2021: From MANTA trial in moderately to severely active ulcerative colitis
Checkmark For MANTA trial in males with inflammatory bowel disease
Aug 2020 - Aug 2020: For MANTA trial in males with inflammatory bowel disease
Terminated
2
139
Europe, US, RoW
Filgotinib, Placebo, Standard of Care
Galapagos NV, Gilead Sciences
Inflammatory Bowel Disease
11/20
10/23
MANTA-RAy, NCT03926195 / 2018-003933-14: Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis

Checkmark From MANTA-RAy trial for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis
Mar 2021 - Mar 2021: From MANTA-RAy trial for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis
Checkmark For MANTA-Ray trial in males with rheumatoid Arthritis, psoriatic Arthritis, ankylosing Spondylitis, or non-radiographic Axial Spondyloarthritis
Aug 2020 - Aug 2020: For MANTA-Ray trial in males with rheumatoid Arthritis, psoriatic Arthritis, ankylosing Spondylitis, or non-radiographic Axial Spondyloarthritis
Completed
2
109
Europe, RoW
Filgotinib, GS-6034, Jyseleca®, Placebo, Standard of Care
Galapagos NV, Gilead Sciences
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographical Axial Spondyloarthritis
08/20
05/23
DARWIN3, NCT02065700 / 2012-003655-11: Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants

Checkmark DARWIN3 trial for RA at ACR 2017
Nov 2017 - Nov 2017: DARWIN3 trial for RA at ACR 2017
Checkmark Interim data from DARWIN 3 trial for RA at EULAR 2017
Jun 2017 - Jun 2017: Interim data from DARWIN 3 trial for RA at EULAR 2017
Completed
2
739
Europe, US, RoW
Filgotinib, GS-6034, GLPG0634
Galapagos NV, Gilead Sciences
Rheumatoid Arthritis
01/23
01/23
DRIMID, NCT06285539: Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Recruiting
2
60
Europe
Filgotinib
UMC Utrecht, Alfasigma S.p.A., ReumaNederland, Autoimmune Research and Collaboration Hub
Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease
12/26
12/26
NCT06043739: Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Completed
1
12
Canada
Filgotinib, GS-6034, GLPG0634, Jyseleca
Galapagos NV
Bioavailability
10/23
11/23
NCT06222034: Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Recruiting
1
10
Europe
Filgotinib, GS-6034, GLPG0634, Jyseleca
Alfasigma S.p.A.
Juvenile Idiopathic Arthritis
01/26
08/26
FIL-M082-501, NCT06246123: A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

Recruiting
N/A
2040
RoW
Non-interventional
Eisai Korea Inc.
Arthritis, Rheumatoid, Colitis, Ulcerative
07/27
07/27
NCT05119452: Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis

Not yet recruiting
N/A
85
NA
Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD), b/tsDMARD: Adalimumab, Infliximab, Golimumab, Certolizumab pegol, Tocilizumab, Sarilumab, Etanercept, Anakinra, Filgotinib, Updacitinib, Tofacitinib, Baricitinib
Medical University of Vienna, Medical University of Graz, Medical University Innsbruck, Hospital Hietzing, Krankenhaus Bruneck
Rheumatoid Arthritis
09/24
09/24
FILOSOPHY, NCT04871919: Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

Active, not recruiting
N/A
1304
Europe
Filgotinib, Jyseleca
Alfasigma S.p.A.
Rheumatoid Arthritis
06/28
06/28
TEMPO, NCT05697159: 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis

Recruiting
N/A
20
Europe
NHS Greater Glasgow and Clyde, Galapagos NV
Rheumatoid Arthritis, Sickness Behavior, Inflammatory Disease, Autoimmune, Pain, Chronic
07/25
10/25
PARROTFISH, NCT05323591: Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

Active, not recruiting
N/A
155
Europe
Filgotinib, Jyseleca
Alfasigma S.p.A.
Rheumatoid Arthritis
09/25
09/25
GALOCEAN, NCT05817942: Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

Recruiting
N/A
600
Europe
Filgotinib
Alfasigma S.p.A.
Ulcerative Colitis
12/27
12/27
STEER, NCT05653791: Early Intestinal Ultrasound in Predicting Treatment Response to Filgotinib in Ulcerative Colitis

Active, not recruiting
N/A
20
Europe
Intestinal ultrasound
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Galapagos NV
Ulcerative Colitis
04/24
10/24
Xifaxan EIR (rifaximin extended intestinal release) / Bausch Health, Alfasigma
2017-003722-33: Phase II clinical trial, conducted in different sites, with random assignation of treatment, where neither the patient or the medical doctor know the assigned treatment, drug or placebo, to evaluate the efficacy and safety of Rifaximin delayed release 400 mg tablet in Patients with Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test Studio clinico di fase II, condotto in siti differenti, con assegnazione random del trattamento, in cui né il paziente né il medico conoscono il trattamento assegnato, attivo o placebo, per valutare efficacia e sicurezza di Rifaximina compresse da 400 mg a rilascio ritardato in pazienti con rosacea papulo-pustolosa moderata-severa e positività al breath test al lattulosio.

Not yet recruiting
2
228
Europe
Rifaximin delayed release 400 mg, Rifaximin-EIR, Coated tablet
ALFASIGMA S.P.A., ALFASIGMA S.P.A.
Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test Rosacea papulo-pustolosa moderata-severa e positività al breath test al lattulosio, Moderate-to-Severe Papulopustular Rosacea and Positive Lactulose Breath Test Rosacea papulo-pustolosa moderata-severa e positività al breath test al lattulosio, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 
NCT05150587: Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

Completed
2
216
US
Rifaximin, Placebo
Alfasigma S.p.A., bioRASI, LLC
Papulopustular Rosacea
10/22
10/22
Sulonex (sulodexide) / Alfasigma
ChiCTR-TRC-09000559: A randomized double-blind parallel placebo trial to evaluate the efficacy and safety of sulodexide on diabetes with marcoalbuminuria.

Completed
4
160
 
Placebo 2 capsules bid for 48 weeks ;Sulodexide 2 capsules bid (100mg/day) for 48 weeks
West China Hospital, Sichuan University; Alfa Wassermann Inc. Italy, Alfa Wassermann Inc. Italy
Diabetes with marcoalbuminuria
 
 
2006-004043-35: Effects of Sulodexide on damaged endothelial Glycocalyx in pAtients with Diabetes Mellitus type II; Reversing damage.

Ongoing
4
26
Europe
Sulodexide, Sulodexide, Sulodexide
diabetes mellitus type II with and without microalbuminuria, damaged glycocalyx
 
 
2015-005113-73: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes

Ongoing
4
52
Europe
Tablet, Capsule, Micardis, Jardiance, Trajenta, Vessel Due F
University Medical Center Groningen, UMCG
Type 2 diabetes with albuminuria, Type 2 diabetes with albumin in urine., Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
2015-005691-26: A rotation study of different albuminuria lowering drug classes to study individual drug response in diabetes

Ongoing
4
26
Europe
Micardis, Jardiance, Trajenta, Vessel Due F
University Medical Center Groningen, University Medical Center Groningen
Type 1 diabetes with albuminuria, Type 1 diabetes with albumin in the urine, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
ChiCTR-IPC-15007029: A study of sulodexide in the treatment of elder patients with diabetic nephropathy (dn)

Not yet recruiting
4
60
 
slodexide 50mg bid po ;conventional treatment
zhejiang hospital; Zhejiang Hospital, self-preparation/drug supplied by pharmaceutical firms for free
diabetic nephropathy
 
 
NCT05252923: Endothelial Protection in Convalescent COVID-19 Patients

Terminated
4
2
RoW
Sulodexide
Pirogov Russian National Research Medical University
Endothelial Dysfunction, Inflammation, Thrombosis, COVID-19
09/22
12/22
2020-000110-15: Study on Sulodexide compared with placebo for the management of leg symptoms in patients with chronic venous disease

Not yet recruiting
3/4
624
RoW, Europe
Sulodexide 250 LSU, [Sulodexide], Capsule, soft, Vessel
Alfasigma S.p.A., ALFASIGMA S.P.A., Alfasigma S.p.A., ALFASIGMA S.P.A.
Chronic Venous Disease, Chronic Venous Disease, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2016-000783-42: A phase 3, prospective, open, pilot, monocentric study to evaluate the effect of sulodexide administered at registered dose on morphology and functional properties of the venous endothelium in patients with chronic venous insufficiency.

Ongoing
3
15
Europe
Capsule, soft, VESSEL DUE F, Sulodexide
Alfa Wassermann Polska Sp. z o.o., Alfa-Wassermann Polska Sp. z o.o.
chronic venous insufficiency, chronic venous insufficiency, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2019-000570-33: Sulodexide (VESSEL®) for the prevention of a recurrent episode of deep vein thrombosis and/or pulmonary embolism in elderly patients Utilizzo del Sulodexide (VESSEL®) per la prevenzione di un nuovo episodio in pazienti anziani che hanno avuto un primo episodio di trombosi venosa profonda e/o embolia polmonare

Not yet recruiting
3
1455
Europe
Vessel, [Sulodexide], Capsule, soft, VESSEL - 250 ULS CAPSULE MOLLI 50 CAPSULE
FONDAZIONE ARIANNA ANTICOAGULAZIONE, ALFASIGMA
Prevention of recurrence after a first episode of VTE Prevenzione della recidiva dopo un primo episodio di tromboembolismo venoso, Prevention of recurrent episode of deep vein thrombosis with or without pulmonary embolism in elderly patients Prevenzione di un nuovo episodio di trombosi venosa profonda con o senza embolia polmonare in pazienti anziani, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT05371925: Endothelial Protection in Post COVID-19 Patients With Sulodexide

Completed
3
206
RoW
Sulodexide, Vessel due F (Alfasgima SpA, Italy)
Centro Medico del Noroeste, Alfasigma S.p.A.
Post COVID-19, Endothelial Dysfunction, Thrombosis
02/24
04/24
2021-002311-64: Treatment of patients with chronic venous disease of the lower extremities using sulodexide Terapie pacientů s chronickým žilním onemocněním dolních končetin pomocí sulodexidu

Not yet recruiting
3
290
RoW
Vessel, Capsule, soft, Vessel
ALFASIGMA CZECH s.r.o., ALFASIGMA CZECH s.r.o.
Chronic primary venous disease of the lower limbs chronické primární žilní onemocnění dolních končetin, Long-term venous disease of the lower limbs Dlouhodobé žilní onemocnění dolních končetin, Diseases [C] - Cardiovascular Diseases [C14]
 
 
Jason, NCT04257487: Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Study)

Recruiting
3
1455
Europe
Sulodexide, VESSEL®, Sulodexide and placebo, VESSEL® and placebo, Placebo, 2 soft capsule of placebo BDI for 12 months
Arianna Anticoagulazione Foundation
Venous Thromboembolism, Anticoagulant, Elderly
12/25
01/27
SuloPrima, NCT05005052: Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities

Recruiting
3
290
RoW
Vessel, Placebo
Value Outcomes Ltd., Alfasigma S.p.A.
Chronic Venous Disease, Chronic Insufficiency Venous
12/23
12/23
NCT06982196: Sulodexide in Controlling the Recurrence of Psoriasis

Enrolling by invitation
3
160
RoW
Sulodexide, Vessel Due F (international brand), Placebo, Matching placebo for sulodexide soft capsules
Xijing Hospital
Psoriasis (PsO), Randomised Controlled Trial
06/26
12/27
2020-002864-30: Sulodexide for chronic heart failure

Not yet recruiting
2
64
Europe
Capsule, VESSEL DUE F
Amsterdam UMC, location AMC, Dutch Heart Foundation
Chronic heart failure, Chronic heart failure, Diseases [C] - Cardiovascular Diseases [C14]
 
 
2022-001958-36: A prospective, randomised, placebo-controlled, investigator-initiated study of the effect of Sulodexide on endothelial protection in convalescent COVID-19 patients. Prospektív, randomizált, placebo kontrollált, vizsgálók által kezdeményezett vizsgálat a Sulodexide endotheliális védelemre gyakorolt hatására gyógyuló COVID-19 betegeknél.

Ongoing
2
200
Europe
Vessel due F, Capsule, soft, Vessel due F
Corporativo de Servicios Médicos Especializados S.A de C.V V (Centro Médico del Noroeste), Pécsi Tudományegyetem; Szegedi Tudományegyetem
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus 2 (SARS-CoV-2) and, thus, being a novel cause of sepsis and the the poor outcome of patients with sepsis was related to systemic microvascular endothelial dysfunction in the vital organs of the body. A koronavírus (SARS-CoV-2) által okozott fertőző betegség kedvezőtlen kimenetelét a létfontosságú szervek szisztémás mikrovaszkuláris endotél diszfunkciójával hozzák kapcsolatba., Systemic microvascular endothelial dysfunction of poor outcome of COVID-19 patients with sepsis COVID-19 fertőzésben szenvedő betegek rossz kimenetelű szisztémás mikrovaszkuláris endotél diszfunkciója, Diseases [C] - Cardiovascular Diseases [C14]
 
 
ChiCTR2200057699: A prospective, controlled, post-marketing exploratory clinical study to evaluate the safety and efficacy of sulodexide in the treatment of adult patients with simple hemodialysis access stenosis after percutaneous transluminal angioplasty

Not yet recruiting
N/A
90
 
Sulodexide soft capsule, oral preparation, 250LSU each time, 2 times a day (morning and evening), continuous medication for a total of 24 weeks. ;Sulodexide soft capsule, oral preparation, 500LSU each time, 2 times a day (morning and evening), continuous medication for a total of 24 weeks. ;None
The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, China Association of Gerontology and Geriatrics
simple hemodialysis access stenosis in adults
 
 
NCT05654233: The Study of Reducing Adverse Effects After Radiofrequency Ablation Combined With Sclerotherapy

Not yet recruiting
N/A
120
RoW
Sulodexide
Chengdu University of Traditional Chinese Medicine
Vascular Diseases, Peripheral, Venous Insufficiency of Leg, Varicose Veins of Lower Limb
08/23
09/23
ChiCTR2300067473: Application of Sulodexide in the Treatment of Refractory Posner-Schlossman Syndrome:A self-controlled Study

Not yet recruiting
N/A
16
 
sulodexide
The Eye of Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University; The Eye of Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, self-finance
Posner-Schlossman Syndrome
 
 
ChiCTR2200060833: Clinical observation on the treatment of proteinuria after renal transplantation with Sulodexide soft capsule

Recruiting
N/A
120
 
Oral sulodexide softgel
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology; Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, ALFA WASSERMANN Pharmaceuticals, Italy
proteinuria after renal transplantation
 
 
ChiCTR2400079929: Changes of vascular endothelial glycocalyx in sepsis and the protective effect of glycosaminoglycan

Not yet recruiting
N/A
70
 
Both groups followed the clinical guidelines, improved pathogenic microorganism monitoring, clearance of infection, early use of antibiotics and hemodynamic support. On this basis, the observation group was treated with glycosaminoglycan (Sulodexide, Alphagemar)[2ml:600LSU/time,1 time /d].; All patients followed the clinical guidelines, improved pathogenic microorganism monitoring, clearance of infection foci, early use of antibiotics and hemodynamic support.
Affiliated Hospital of Hangzhou Normal University; Affiliated Hospital of Hangzhou Normal University, Hangzhou city technology bureau to guide project (20220919 y023)
sepsis
 
 
ACTRN12611000721909: Sulodexide effect on walking ability in patients with intermittent claudication

Not yet recruiting
N/A
50
 
Georges Tabet, Georges Tabet
Intermittent claudication, Peripheral arterial occlusive disease
 
 
brilacidin rectal / Innovation Pharma
No trials found

Download Options